T. Rowe Price Associates
BBNX

T. Rowe Price Associates’s Beta Bionics BBNX Stock Holding History

T. Rowe Price Associates’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Sell
35,472
-497,277
-93% -$7.36M ﹤0.01% 2602
2025
Q4 		$16.2M Buy
532,749
+45,091
+9% +$1.2M ﹤0.01% 1116
2025
Q3 		$9.69M Buy
487,658
+169,715
+53% +$2.98M ﹤0.01% 1237
2025
Q2 		$4.63M Sell
317,943
-318,261
-50% -$4.51M ﹤0.01% 1294
2025
Q1 		$7.79M Buy
+636,204
New +$11.9M ﹤0.01% 1159

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's BBNX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Beta Bionics (BBNX) stake by 93% in Q1 2026, selling an estimated $7.36M and leaving 35,472 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #2602.

T. Rowe Price Associates first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $16.2M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • T. Rowe Price Associates held 35,472 shares of Beta Bionics worth $356K as of Q1 2026.
  • T. Rowe Price Associates sold 497,277 Beta Bionics shares in Q1 2026, an estimated $7.36M.
  • Beta Bionics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2602 holding.
  • T. Rowe Price Associates first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • T. Rowe Price Associates's Beta Bionics position peaked at $16.2M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.